Table 1. Clinical characteristics by condition.
| iMCD | UCD | HHV-8+ MCD | Lymphoma | |
|---|---|---|---|---|
| Number of samples | 11 | 12 | 2 | 6 |
| Age at diagnosis | 48 ± 20 | 40 ± 14 | 45 | NR |
| Gender | 64% Male | 42% Male | 100% Male | NR |
| Relapsing disease | 4/11 | 0/9 | 1/1 | NA |
| Histopathology | 6 PC, 3 HV, 2M | 11 HV, 1M | 2 PB | NA |
| CRP (mg/L) | 113.2 ± 106.3 (n = 6) | 0.5 ± 0.5 (n = 5) | 17.5 | NR |
| ESR (mm/hr) | 81.6 ± 31.4 (n = 6) | 7.4 ± 4.8 (n = 5) | 57 | NR |
| TAFRO clinical subtype | 3/11 | 0/7 | NR | NA |
Clinical characteristics are presented for all samples analyzed by VirCapSeq-VERT. Histopathology specifically refers to Castleman disease histopathology subtype. PC, plasmacytic; HV, hyaline vascular; M, mixed PC and HV; PB, plasmablastic. Relapsing disease and presence of TAFRO syndrome are specific to Castleman disease. TAFRO, thrombocytopenia, anasarca, fever, reticulin myelofibrosis/renal dysfunction, organomegaly; iMCD, idiopathic multicentric Castleman disease; UCD, unicentric CD; HHV-8+ MCD, Kaposi sarcoma-associated/human herpes virus(HHV)-8 positive MCD; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Values are presented as mean ± standard deviation, as appropriate.